Results 141 to 150 of about 10,402 (207)

Erratum: Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies. [PDF]

Am J Cancer Res
Ataie-Kachoie P, Pillai K, Badar S, Akhter J, Morris DL.   +4 more
europepmc   +1 more source

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas. [PDF]

Cancers (Basel), 2023
Buonadonna A, Scalone S, Lombardi D, Fumagalli A, Guglielmi A, Lestuzzi C, Polesel J, Canzonieri V, Lamon S, Giovanis P, Gagno S, Corona G, Mascarin M, Belluco C, De Paoli A, Fasola G, Puglisi F, Miolo G.   +17 more
europepmc   +1 more source

Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial. [PDF]

Oncologist
Tang L, He M, Geng C, Fan Z, Ling R, Qiao G, Cai L, Luo T, Jin F, Wang H, Zhang A, Zhang H, Zeng X, Wang X, Jiang M, Wang Z, Shao Z.   +16 more
europepmc   +1 more source

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer. [PDF]

Front Cell Dev Biol
Shen Y, Hua Q, Dong M, Jin W, Hu X, Gu K.   +5 more
europepmc   +1 more source

Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin. [PDF]

Cost Eff Resour Alloc
Chapola JC, Kleber SL, Krown SE, Painschab M.   +3 more
europepmc   +1 more source

Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin. [PDF]

Front Oncol
Quan X, Li J, Sun J, Xing X, Liu D, Ji H, Guo Q.   +6 more
europepmc   +1 more source

Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. [PDF]

BMJ Oncol
Gabizon AA, Gabizon-Peretz S, Modaresahmadi S, La-Beck NM.   +3 more
europepmc   +1 more source

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.

JAMA Oncol, 2022
Wang T, Tang J, Yang H, Yin R, Zhang J, Zhou Q, Liu Z, Cao L, Li L, Huang Y, Jiang K, Wang W, She F, Guan N, Hou Z, Li N, Wu L.   +16 more
europepmc   +1 more source

Clinical Benefit of Pegylated Liposomal Doxorubicin and High Prevalence of Pre-Existing Psychiatric Conditions in Patients with Desmoid-Type Fibromatosis. [PDF]

Cancers (Basel)
Freire AE, Skubitz KM.
europepmc   +1 more source

Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study. [PDF]

Oncologist
Zhang Y, Yuan Z, Zhang GN, Li QS, Cui MH, Cheng WJ, Meng YG, Wu XH, Yue Y, Wang L, Hou JQ, Li CZ, Qu PP, Sun LX, Tao GS, Li GL, Chen YQ, Ren F, Cao DY, Shen K.   +19 more
europepmc   +1 more source